公开(公告)号：US20120093884A1

公开(公告)日：2012-04-19

申请号：US13269326

申请日：2011-10-07

Applicant: Timo VESIKARI ,  Vesna BLAZEVIC ,  Kirsi NURMINEN ,  Leena HUHTI ,  Suvi LAPPALAINEN ,  Eeva JOKELA

Inventor： Timo VESIKARI ,  Vesna BLAZEVIC ,  Kirsi NURMINEN ,  Leena HUHTI ,  Suvi LAPPALAINEN ,  Eeva JOKELA

IPC: A61K9/00 ,  A61P31/14 ,  C12P21/00 ,  A61K39/295

CPC classification number: A61K39/125 ,  A61K39/12 ,  A61K39/15 ,  A61K2039/5258 ,  A61K2039/70 ,  C12N2710/14143 ,  C12N2720/12323 ,  C12N2720/12334 ,  C12N2770/16023 ,  C12N2770/16034 ,  C12N2799/026 ,  C12N2800/22

Abstract: The present invention relates to a combined norovirus and rotavirus vaccine for prevention of norovirus and rotavirus infection and/or viral-induced diarrheal and vomiting diseases in man. More specifically, the invention comprises a method of preparing combination vaccine compositions comprising norovirus and rotavirus antigens, in particular mixtures of norovirus VLPs and rotavirus recombinant VP6 protein or double-layered VP2/VP6 VLPs. In addition, the invention relates to methods of inducing an immune response.

Abstract translation: 本发明涉及用于预防诺如病毒和轮状病毒感染和/或病毒诱导的人体腹泻和呕吐疾病的组合诺瓦病毒和轮状病毒疫苗。 更具体地，本发明包括制备包含诺如病毒和轮状病毒抗原，特别是诺如病毒VLP和轮状病毒重组VP6蛋白或双层VP2 / VP6 VLP的混合物的组合疫苗组合物的方法。 此外，本发明涉及诱导免疫应答的方法。

公开(公告)号：US10023844B2

公开(公告)日：2018-07-17

申请号：US14904364

申请日：2014-05-21

Applicant: UMN PHARMA INC. ,  Timo Vesikari ,  Vesna Blazevic

Inventor： Masahiro Okada ,  Akiko Mukai ,  Tomonori Nishino ,  Daisuke Arinobu ,  Hiroyuki Ito ,  Mamoru Satoh

IPC: C12N7/02 ,  C12N7/00

CPC classification number: C12N7/00 ,  C12N2770/16023 ,  C12N2770/16051

Abstract: The present invention aims at establishing a novel means for purifying norovirus VLPs. There is provided a purification method of norovirus virus-like particles, comprising: contacting solution containing norovirus virus-like particles with support for hydroxyapatite chromatography, binding the virus-like particles to the support, subsequently washing the support with buffer, and then eluting the virus-like particles from the support with buffer containing phosphate, wherein the phosphate concentration of the buffer used for elution is less than 10 mM.

公开(公告)号：US07431931B2

公开(公告)日：2008-10-07

申请号：US10181908

申请日：2001-01-26

Applicant: Albert Z. Kapikian ,  Robert Chanock ,  Timo Vesikari

Inventor： Albert Z. Kapikian ,  Robert Chanock ,  Timo Vesikari

IPC: A61K39/15 ,  A61K39/12

CPC classification number: A61K39/15 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/542 ,  A61K2039/545 ,  A61K2039/55 ,  C12N2720/12334

Abstract: The present invention provides compositions for making a medicament and methods for the administration of a vaccine compositions for protection against human rotaviral disease without significant reactogenicity. Human x rhesus reassortant rotavirus compositions were made which when administered during the first 7 to about 10 days of life, provided a composition which was non-reactogenic followed by booster immunizations at 16 to 18 weeks or 14 to 20 weeks, up to 1 year of age. The immune response induced by the initial neonatal administration of the live rotavirus vaccine composition protects the infant from the reactogenicity of the composition when administered as a second vaccine dose at or after 2 months of age. Administration of the immunogenic composition also is expected to ablate or significantly diminish the increase in the excess of intussusception observed 3 to 7 days following administration of the initial dose of rotavirus vaccine at about 2 to 4 months.

Abstract translation: 本发明提供了用于制备药物的组合物和用于施用用于防止人类轮状病毒病而没有显着的反应原性的疫苗组合物的方法。 制备人x恒河猴重配轮状病毒组合物，其在生命的头7至10天期间施用时，提供了在16至18周或14至20周，不超过1年的非 - 年龄。 由活轮状病毒疫苗组合物的初始新生儿施用诱导的免疫应答在2个月龄或之后作为第二种疫苗剂量施用时保护了婴儿免受组合物的反应原性。 免疫原性组合物的给药预期在约2-4个月施用初始剂量的轮状病毒疫苗后3至7天可以消融或显着减少肠套叠过量的增加。

公开(公告)号：US08895015B2

公开(公告)日：2014-11-25

申请号：US13269326

申请日：2011-10-07

Applicant: Timo Vesikari ,  Vesna Blazevic ,  Kirsi Nurminen ,  Leena Huhti ,  Suvi Lappalainen ,  Eeva Jokela

Inventor： Timo Vesikari ,  Vesna Blazevic ,  Kirsi Nurminen ,  Leena Huhti ,  Suvi Lappalainen ,  Eeva Jokela

IPC: A61K39/00 ,  A61K39/12 ,  A61K39/15 ,  A61K39/125 ,  C12Q1/70

CPC classification number: A61K39/125 ,  A61K39/12 ,  A61K39/15 ,  A61K2039/5258 ,  A61K2039/70 ,  C12N2710/14143 ,  C12N2720/12323 ,  C12N2720/12334 ,  C12N2770/16023 ,  C12N2770/16034 ,  C12N2799/026 ,  C12N2800/22

Abstract: The present invention relates to a combined norovirus and rotavirus vaccine for prevention of norovirus and rotavirus infection and/or viral-induced diarrheal and vomiting diseases in man. More specifically, the invention comprises a method of preparing combination vaccine compositions comprising norovirus and rotavirus antigens, in particular mixtures of norovirus VLPs and rotavirus recombinant VP6 protein or double-layered VP2/VP6 VLPs. In addition, the invention relates to methods of inducing an immune response.

Abstract translation: 本发明涉及用于预防诺如病毒和轮状病毒感染和/或病毒诱导的人体腹泻和呕吐疾病的组合诺瓦病毒和轮状病毒疫苗。 更具体地，本发明包括制备包含诺如病毒和轮状病毒抗原，特别是诺如病毒VLP和轮状病毒重组VP6蛋白或双层VP2 / VP6 VLP的混合物的组合疫苗组合物的方法。 此外，本发明涉及诱导免疫应答的方法。

公开(公告)号：US20080292660A1

公开(公告)日：2008-11-27

申请号：US11994640

申请日：2006-07-07

Applicant: Albert Z. Kapikian ,  Lone Simonsen ,  Timo Vesikari ,  Yasutaka Hoshino ,  David M. Morens ,  Robert M. Chanock ,  John R. La Montagne ,  Brian R. Murphy

Inventor： Albert Z. Kapikian ,  Lone Simonsen ,  Timo Vesikari ,  Yasutaka Hoshino ,  David M. Morens ,  Robert M. Chanock ,  John R. La Montagne ,  Brian R. Murphy

IPC: A61K39/15 ,  A61P31/14

CPC classification number: A61K39/15 ,  A61K39/12 ,  A61K2039/70 ,  C12N2720/12334

Abstract: The present invention provides vaccine compositions for protection against human rotaviral disease designed for use in particular areas of the world. Human×bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined with other VP7 serotypes typically found in the area of interest into a multivalent formulation which provides a high degree of infectivity and immunogenicity. Methods and an administration protocol for producing an immunogenic response without producing an increased risk of intussusception are also provided.

Abstract translation: 本发明提供了用于防止设计用于世界特定地区的人类轮状病毒病的疫苗组合物。 将包含人轮状病毒的四种临床上最重要的VP7血清型中的每一种的人类重链轮状病毒与通常在感兴趣区域中发现的其它VP7血清型组合成多价制剂，其提供高度的感染性和免疫原性。 还提供了用于产生免疫原性反应而不产生增加的肠套叠风险的方法和管理方案。

公开(公告)号：US20160215271A1

公开(公告)日：2016-07-28

申请号：US14904315

申请日：2014-05-21

Applicant: Timo VESIKARI ,  Vesna BLAZEVIC ,  UMN PHARMA INC.

Inventor： Masahiro OKADA ,  Akiko MUKAI ,  Tomonori NISHINO ,  Daisuke ARINOBU ,  Hiroyuki TO ,  Mamoru SATOH

IPC: C12N7/00

CPC classification number: C12N7/00 ,  A61K39/12 ,  A61K2039/5256 ,  A61K2039/5258 ,  C07K14/005 ,  C12N2710/14043 ,  C12N2770/16022 ,  C12N2770/16023 ,  C12N2770/16034 ,  C12N2770/16051

Abstract: The present invention aims at establishing a means for obtaining highly pure virus-like particles by a simple method. There is provided a production method for culture containing virus-like particles, comprising: transforming insect cells with baculovirus vector containing a viral nucleic acid sequence; and cultivating the insect cells, wherein the culture is obtained after continuing cultivating the insect cells until the viability of the insect cells reaches 10% or less.

Abstract translation: 本发明旨在通过简单的方法建立获得高纯度病毒样颗粒的方法。 提供含有病毒样颗粒的培养物的制备方法，包括：用含有病毒核酸序列的杆状病毒载体转化昆虫细胞; 培养昆虫细胞，其中在继续培养昆虫细胞直到昆虫细胞的存活率达到10％以下之前获得培养物。

公开(公告)号：US20160168543A1

公开(公告)日：2016-06-16

申请号：US14904364

申请日：2014-05-21

Applicant: Timo VESIKARI ,  Vesna BLAZEVIC ,  UMN PHARMA INC.

Inventor： Masahiro OKADA ,  Akiko MUKAI ,  Tomonori NISHINO ,  Daisuke ARINOBU ,  Hiroyuki TO ,  Mamoru SATOH

IPC: C12N7/00

CPC classification number: C12N7/00 ,  C12N2770/16023 ,  C12N2770/16051

Abstract: The present invention aims at establishing a novel means for purifying norovirus VLPs. There is provided a purification method of norovirus virus-like particles, comprising: contacting solution containing norovirus virus-like particles with support for hydroxyapatite chromatography, binding the virus-like particles to the support, subsequently washing the support with buffer, and then eluting the virus-like particles from the support with buffer containing phosphate, wherein the phosphate concentration of the buffer used for elution is less than 10 mM.

Abstract translation: 本发明旨在建立一种纯化诺如病毒VLP的新方法。 提供了诺如病毒病毒样颗粒的纯化方法，其包括：将含有诺如病毒病毒样颗粒的溶液与羟基磷灰石层析用载体接触，将病毒样颗粒结合到载体上，随后用缓冲液洗涤载体， 来自含有磷酸盐缓冲液的载体的病毒样颗粒，其中用于洗脱的缓冲液的磷酸盐浓度小于10mM。

公开(公告)号：US08168202B2

公开(公告)日：2012-05-01

申请号：US11994640

申请日：2006-07-07

Applicant: Albert Z. Kapikian ,  Lone Simonsen ,  Timo Vesikari ,  Yasutaka Hoshino ,  David M. Morens ,  Robert M. Chanock ,  John R. La Montagne ,  Mary Elaine La Montagne, legal representative ,  Brian R. Murphy

Inventor： Albert Z. Kapikian ,  Lone Simonsen ,  Timo Vesikari ,  Yasutaka Hoshino ,  David M. Morens ,  Robert M. Chanock ,  John R. La Montagne ,  Brian R. Murphy

IPC: A61K39/15

CPC classification number: A61K39/15 ,  A61K39/12 ,  A61K2039/70 ,  C12N2720/12334

Abstract: The present invention provides vaccine compositions for protection against human rotaviral disease designed for use in particular areas of the world. Human× bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined with other VP7 serotypes typically found in the area of interest into a multivalent formulation which provides a high degree of infectivity and immunogenicity. Methods and an administration protocol for producing an immunogenic response without producing an increased risk of intussusception are also provided.

Abstract translation: 本发明提供了用于防止设计用于世界特定地区的人类轮状病毒病的疫苗组合物。 将包含人轮状病毒的四种临床上最重要的VP7血清型中的每一种的人×牛重配轮状病毒与通常在感兴趣区域中发现的其它VP7血清型组合成多价制剂，其提供高度的感染性和免疫原性。 还提供了用于产生免疫原性反应而不产生增加的肠套叠风险的方法和管理方案。